Media stories about ReWalk Robotics (NASDAQ:RWLK) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ReWalk Robotics earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the medical device company an impact score of 47.0096624142184 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
A number of analysts have issued reports on the company. Zacks Investment Research upgraded ReWalk Robotics from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research report on Thursday, November 9th. Canaccord Genuity restated a “buy” rating and set a $3.00 target price on shares of ReWalk Robotics in a research report on Monday, November 6th. Finally, Jefferies Group reduced their target price on ReWalk Robotics from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. ReWalk Robotics has a consensus rating of “Buy” and a consensus price target of $3.00.
ReWalk Robotics (RWLK) remained flat at $$1.15 during midday trading on Monday. 249,500 shares of the stock traded hands, compared to its average volume of 402,004. ReWalk Robotics has a 52 week low of $1.05 and a 52 week high of $3.60. The company has a quick ratio of 1.65, a current ratio of 2.02 and a debt-to-equity ratio of 7.46.
ReWalk Robotics (NASDAQ:RWLK) last released its earnings results on Thursday, November 2nd. The medical device company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.10. ReWalk Robotics had a negative return on equity of 568.25% and a negative net margin of 346.14%. The company had revenue of $1.70 million during the quarter, compared to analyst estimates of $1.63 million. During the same quarter in the previous year, the company posted ($0.62) EPS. ReWalk Robotics’s revenue for the quarter was up 21.4% on a year-over-year basis. analysts expect that ReWalk Robotics will post -1.14 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “ReWalk Robotics (NASDAQ:RWLK) Receives News Impact Score of 0.15” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/04/rewalk-robotics-rwlk-receiving-somewhat-positive-press-coverage-study-shows.html.
ReWalk Robotics Company Profile
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.
Receive News & Ratings for ReWalk Robotics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics Ltd and related companies with MarketBeat.com's FREE daily email newsletter.